Résumé
Les tumeurs stromales digestives sont les tumeurs mésenchymateuses les plus fréquentes du tube digestif. Ces tumeurs ont fait l’objet de nombreuses controverses en termes d’histogenèse et de classification. Elles s’intègrent maintenant dans un cadre nosologique précis depuis la découverte de l’expression par les cellules tumorales de la protéine c-kit. Leur potentiel de malignité est souvent difficile à évaluer. Le diagnostic est confirmé par l’étude anatomopathologique de la pièce opératoire complétée par l’étude immunohistochimique. Le traitement est essentiellement chirurgical, la radiothérapie et la chimiothérapie étant peu efficaces. Ces tumeurs sont particulièrement d’actualité depuis la découverte d’un traitement des formes malignes agressives localement avancées, inopérables et/ou métastatiques par un inhibiteur de la tyrosine-kinase (STI 571 ou Glivec®).
Abstract
Gastrointestinal stromal tumors (GISTs) are the most frequent mesenchymal tumors of the digestive tract. These tumors are the subject of numerous controversies in terms of histogenesis and classification. They now become integrated into a precise nosologic frame (executive) since the discovery of the expression by the tumoral cells of the protein c-kit. Their malignant potential is often difficult to estimate. The diagnosis is confirmed by the anatomopathologic study completed by the immunohistochimic study. The treatment is essentially surgical, with radiotherapy and chemotherapy being little effective. These tumors are particularly of current importance since the discovery of a treatment for the locally advanced, aggressive malignant forms, inoperable and/or metastatic by an inhibitor of the tyrosine kinase (STI 571 or Glivec®).
Références
Mieittinen M, Lasota J (2001). Gastrointestinal stromal tumors — definition, clinical, histological, immunohistochemical and molecular features and differential diagnosis. Virchows Arch 438:1–12
Nishida T, Hirota S (2000). Biological and clinical review of stromal tumors in the gastrointestinal tract. Histol Histopathol 15:1293–301
Hirota S, Isozaki K, Moriyama Y, et al (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279:577–80
Bedossa P (1997) Les tumeurs stromales du tube digestif ? Ann Pathol 17:76–8, 350-6
Berman J, O’Leary TJ (2001) Gastrointestinal stromal tumor workshop. Human Pathol 32:578–82
Strickland L, Letson GD, Muro-Cacho CA (2000) Gastrointestinal stromal tumors. Cancer Control 8:252–61
Scoazec JY (2000) C-kit et tumeurs stromales gastro-intestinales: plus qu’un nouveau marqueur. Ann Pathol 20:91–2
Mieittinen M, Sobin LH, Sarlomo-Rikala M (2000) Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD 117 (kit). Mod Pathol 13:1134–42
Pidhorecky I, Cheney RT, Kraybill WG, et al (2000) Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management. Ann Surg Oncol 7:705–12
Rosch T, Lorenz R, Dancygier H, et al (1992) Endosonographic diagnosis of submucosal upper gastrointestinal tract tumors. Scand J Gastroenterol 27:1–8
Ray-Coquard I, Le Cesne A, Blay JY (2001) STI 571 et tumeurs stromales digestives. Bull Cancer 88:661–2
Alaton J, Coindre JM, Cvitkovich F (2001) Tumeurs stromales digestives. Gastroenterol Clin Biol 25:473–82
Palazzo L, Landi B, Cellier C, et al (2000) Endosonographic features predictive of benign and malignant smooth muscle tumors. Gut 46:88–92
Wiersema MJ, Vilmann P, Giovaninni M, et al (1997) Endosonography-guided fine-needle aspiration biopsy: diagnostic accuracy and complication assessment. Gastroenterology 112:1087–95
Chak A, Canto MI, Rosch T, et al (1997) Endosonographic differentiation of benign and malignant stromal cell tumors. Gastrointest Endosc 45:468–73
Nishida T, Nakamura J, Taniguchi M, et al (2000) Clinicopathological features of gastric stromal tumors. J Exp Clin Cancer Res 19:417–25
Plaat BE, Hollema H, Molenaar WM, et al (2000) Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. J Clin Oncol 18:3211–20
Blanke CD, Von Mehren M, Joensuu H, et al (2001) Evaluation of the Safety and efficacy of an oral molecularly-targeted therapy, STI 571, in patients (Pts) with unresectable or metastatic gastrointestinal stromal tumors (GIST) expressing c-kit (CD 117). Proceeding of the American Society of Clinical Oncology: Abstract 1
Taniguchi M, Nishida T, Hirota S, et al (1999) Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 59:4297–300
Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al (2001) Effect of the tyrosine kinase inhibitor STI 571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344:1052–6
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Moujahid, M., Tajdine, M.T., Achour, A. et al. Les tumeurs stromales gastriques : à propos de trois cas. J Afr Cancer 7, 59–63 (2015). https://doi.org/10.1007/s12558-013-0277-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12558-013-0277-6